

Title: Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease (CAG-00460N)

Decision: The Centers for Medicare & Medicaid Services (CMS) has developed a national coverage determination (NCD) establishing coverage for Food and Drug Administration (FDA) approved monoclonal antibodies directed against amyloid for the treatment of Alzheimer's disease (AD) when furnished in accordance with coverage criteria under coverage with evidence development (CED) for patients who have a clinical diagnosis of mild cognitive impairment (MCI) due to AD or mild AD dementia, both with confirmed presence of amyloid beta pathology consistent with AD.

What this means: Medicare will cover FDA-approved monoclonal antibody drugs that target amyloid (or plaque), also referred to as anti-amyloid drugs, for the treatment of Alzheimer's disease for members who meet criteria and are enrolled in an approved clinical trial. Please refer to the final decision memo for all coverage criteria.

Currently, Aduhelm™ (aducanumab) is the only drug in this class that has been granted approval by the FDA for the treatment of Alzheimer's disease based on evidence that it may reduce plaque on the brain.

Effective: April 7, 2022

This announcement can be found at: [Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease \(CAG-00460N\)](#)

HealthPartners is a health plan that contracts with both Medicare and the Minnesota Medical Assistance (Medicaid) program to provide benefits of both programs to enrollees. HealthPartners is also a Cost plan and PPO plan with a Medicare contract. Enrollment in HealthPartners depends on contract renewal. HealthPartners UnityPoint Health is a PPO plan with a Medicare contract. Enrollment in HealthPartners UnityPoint Health depends on contract renewal.

H2462_90242 IR Approved 06/2015
H3416_90242 IR Approved 06/2017
H2422_90242 IR Approved 07/2015
H4882_90242 IR Approved 03/2018